a16z and Section 32 Lead $28M Series A in Function Oncology

City of Hope Invests $33M in AccessHope (Series B)

April 25, 2024

Healthcare Services

AccessHope, a City of Hope–founded company that delivers oncology expertise to employers, health plans and local oncologists, raised $33 million in a Series B led by City of Hope. The funding will support product and technology development, expansion of its oncology network, and entry into new markets including health plans, Medicare and government; Bradley Kreick was named CEO as part of the company’s next growth phase.

Ampersand Capital Partners Leads $18.5M Growth Investment in Genezen

November 2, 2023

Biotechnology

Genezen closed an $18.5 million follow-on growth equity financing led by Ampersand Capital Partners to accelerate expansion of its viral vector development and GMP manufacturing capabilities. The capital will support build-out and technology investments at Genezen's facilities (including the Fishers, Indiana GMP viral vector site) to scale retroviral, lentiviral and AAV vector production and support additional customer programs.

Fulgent Genetics Acquires Fulgent Pharma

November 7, 2022

Biotechnology

Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.

Integrity Growth Partners Leads $16M Growth Investment in Eon

April 6, 2022

Healthcare Services

Integrity Growth Partners led a $16 million minority growth equity investment in Eon, the Denver-based provider of incidental findings and screening patient management software. The round included participation from UCHealth's CARE Innovation Center, the CU Healthcare Innovation Fund, and 25m Health and will fund accelerated growth, expanded deployments across health systems, and product development while leaving Eon founder-led and independent.

Ampersand Capital Partners Invests in Genezen Laboratories

January 5, 2021

Biotechnology

Ampersand Capital Partners has made a majority growth-equity investment in Genezen Laboratories, a cell and gene therapy CDMO, to fund completion of a 25,000 sq. ft. cGMP lentiviral vector production facility and expand process development and analytical testing capabilities. The capital will support Genezen's capability expansion across upstream/downstream processing, analytical testing, and cGMP vector production to serve early‑phase and growth-stage cell and gene therapy developers.

Summa Equity Acquires Majority Stake in Sengenics

October 14, 2020

Biotechnology

Summa Equity Fund II has acquired a majority stake in Sengenics, a functional proteomics company that commercialises the KREX technology for full‑length, correctly folded protein production and autoantibody detection. The investment will support Sengenics' product development, global expansion and accelerated commercial adoption across pharma, academic research and diagnostics.